Therapeutic challenges in the management of gout in the elderly

Geriatrics

Volumn 63, Issue 7, 2008, Pages 13-20

  Singh, Harinder ^a   Torralba, Karina D ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Elderly; Gout; Hyperuricemia

Indexed keywords

ALLOPURINOL; ASCORBIC ACID; BENZOBROMARONE; CALCIUM PYROPHOSPHATE; COLCHICINE; CORTICOSTEROID; CORTICOTROPIN; ETANERCEPT; FEBUXOSTAT; FENOFIBRATE; IBUPROFEN; INDOMETACIN; INFLIXIMAB; LOSARTAN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PLACEBO; PREDNISONE; PROBENECID; RASBURICASE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALICYLIC ACID DERIVATIVE; SULFINPYRAZONE; TRIAMCINOLONE ACETONIDE; URATE; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR; ANTIGOUT AGENT;

COMORBIDITY; CONFUSION; CONSTIPATION; DEHYDRATION; DIARRHEA; DIET THERAPY; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; ELDERLY CARE; EXERCISE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GOUT; HEPATITIS; HUMAN; HYPERURICEMIA; KIDNEY DISEASE; KIDNEY FAILURE; LIVER DISEASE; LIVER TOXICITY; LOW DRUG DOSE; MEASLES LIKE RASH; MYOCARDIAL DISEASE; NARCOTIC DEPENDENCE; NEPHROLITHIASIS; NEUROMUSCULAR DISEASE; RASH; SHORT SURVEY; VASCULITIS; VOMITING; AGED; CLASSIFICATION; FEMALE; GERIATRICS; MALE; REVIEW;

AGED; FEMALE; GERIATRICS; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE;

EID: 47749120633     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (38)

1. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther. 2006; 8 Suppl 1:S2.
2. Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol. 29(11):2403-2406.
3. Wallace K, Riedel A, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004;31(8):1582-1587.
4. Fam AG. Gout in the elderly. Clinical presentation and treatment. Drugs Aging. 1998;13(3):229-243.
5. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-115.
6. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54(8):2688-2696.
7. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20:895-900.
8. Schlesinger N. Diagnosis of gout: clinical, laboratory, and radiologic findings. Am J Manag Care. 2005;11(15 Suppl):S443-450.
9. Shah K, Spear J, Nathanson LA, McCauley J, Edlow JA. Does the presence of crystal arthritis rule out septic arthritis? J Emerg Med. 2007;32(1):23-26.
10. Mikuls TR, MacLean CH, Olivieri J, et al. Quality of care indicators for gout management. Arthritis Rheum. 2004;50(3):937-943.
11. Singh JA, Hodges JS, Toscano JP, Asch SM. Quality of care for gout in the US needs improvement. Arthritis Rheum. 2007;57(5):822-829.
12. Ene-Stroescu D, Gorbien MJ. Gouty arthritis. A primer on late-onset gout. Geriatrics. 2005;60(7):24-31.
13. Harris MD, Siegel LB, Alloway JA. Gout and hyperuricemia. Am Fam Physician. 1999;59(4):925-934.
14. Geriatric Medicine: An Evidence Based Approach - 4th Ed. (2003): Chapter 42. Rheumatologic Diseases - Daniel J. Brauner, Leif B. Sorensen, and Michael H. Ellman.
15. Kang EH, Lee EY, Lee YJ, Song YW, Lee EB. Clinical features and risk factors of post-surgical gout. [Published online before print November 12, 2007]. Ann Rheum Dis.
16. Schlesinger N, Baker DG, Beutler AM, Hoffman BI, Schumacher HR Jr. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol. 2002;29(2):331-334.
17. Hoskison KT, Wortmann RL. Management of gout in older adults: barriers to optimal control. Drugs Aging. 2007;24(1):21-36.
18. Schumacher HR Jr, Boice JA, Daikh DI, et al. Randomized double blind trial of etoricoxib and indomethacin in treatment of gouty arthritis. BMJ. 2002;324(7352): 1488-1492.
19. Willburger RE, Mysler E, Derbot J, Jung T, et al. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. Rheumatology (Oxford). 2007;46:1126-1132.
20. Fernández C, Noguera R, González JA, Pascual E. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol. 1999;26(10):2285-2286.
21. Schlesinger N. Overview of the management of acute gout and the role of adrenocorticotropic hormone. Drugs. 2008;68(4):407-415.
22. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007;46(8):1372-1374.
23. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendation for gout. Part II: management report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312-1324.
24. Schlesinger N. Reassessing the safety of intravenous and compounded injectable colchicine in acute gout treatment. Expert Opin Drug Saf. 2007;6(6):625-629.
25. Dalbeth N, Collis J, Gregory K, Clark B, Robinson E, McQueen FM. Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology (Oxford). 2007;46(12):1804-1807.
26. Yamanaka H, Togashi R, Hakoda M, et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol. 1998;431:13-18.
27. Emmerson BT. The management of gout. N Engl J Med. 1996;334(7):445-451.
28. Stamp LK, O'Donnell JL, Chapman PT. Emerging therapies in the long-term management of hyperuricemia and gout. Intern Med J. 2007;37(4):258-266.
29. Huang HY, Appel LJ, Choi MJ, et al. The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial. Arthritis Rheum. 2005;52(6):1843-1847.
30. Gao X, Curhan G, Forman JP, Asherio A, Choi HK. Vitamin C intake and serum uric acid concentration in men. [Published online before print May 1, 2008]. J Rheumatol.
31. Hoskison TK, Wortmann RL. Advances in the management of gout and hyperuricaemia. Scand J Rheumatol. 2006;35(4):251-260.
32. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, et al. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis. 2001;60(10):981-983.
33. Wortmann RL. Recent advances in the management of gout and hyperuricaemia. Curr Opin Rheumatol. 2005;17(3):319-324.
34. Fitzgerald BT, Setty A, Mudgal CS. Gout affecting the hand and wrist. J Am Acad Orthop Surg. 2007;15(10):625-635.
35. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450-2461.
36. Chatham WW, Saag K. Is febuxostat a more effective treatment for hyperuricemia and gout than allopurinol? Nat Clin Pract Rheumatol. 2006;2(5):241-242.
37. Richette P, Brière C, Hoenen-Clavert V, Loeuille D, Bardin T. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol. 2007;34(10):2093-2098.
38. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28.